OKYO Pharma director acquires 25,000 shares

OKYO Pharma Ltd director and ten percent owner Gabriele M. Cerrone, through Panetta Partners Limited, reported a grant/award acquisition of 25,000 shares of common stock at $1.40 per share on July 20, 2026.

Accepted by SEC EDGAR 07/21/2026 - 04:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OKYO Pharma Ltd director and ten percent owner Gabriele M. Cerrone, through Panetta Partners Limited, reported a grant/award acquisition of 25,000 shares of common stock at $1.40 per share on July 20, 2026. Following this indirect transaction, his reported holdings via that entity are 10,851,416 shares.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider CERRONE GABRIELE M

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	COMMON STOCK	25,000	$1.40	$35K

Holdings After Transaction: COMMON STOCK — 10,851,416 shares (Indirect, Via Panetta Partners Limited)

Key Figures

Shares acquired: 25,000 shares Grant price: $1.40 per share Indirect holdings after transaction: 10,851,416 shares

3 metrics

Shares acquired 25,000 shares Grant/award acquisition of common stock on July 20, 2026

Grant price $1.40 per share Price for the 25,000-share grant/award acquisition

Indirect holdings after transaction 10,851,416 shares Common stock held indirectly via Panetta Partners Limited after the grant

Key Terms

grant/award acquisition, indirect ownership, Rule 10b5-1, ten percent owner

4 terms

grant/award acquisition financial

"transaction_action": "grant/award acquisition""

indirect ownership financial

"ownership_type": "indirect""

Rule 10b5-1 regulatory

"aff_10b5_one": false (document-level Rule 10b5-1 checkbox)"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

ten percent owner regulatory

""is_ten_percent_owner": 1"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did OKYO (OKYO) recently report?

OKYO Pharma reported that director and ten percent owner Gabriele M. Cerrone received a grant/award of 25,000 common shares at $1.40 per share. The transaction was reported as an indirect acquisition through Panetta Partners Limited on July 20, 2026.

How many OKYO (OKYO) shares does Gabriele M. Cerrone now hold indirectly?

After the reported grant/award, Gabriele M. Cerrone’s indirect holdings total 10,851,416 OKYO Pharma common shares. These shares are reported as being held via Panetta Partners Limited, reflecting his position as a director and ten percent owner of the company.

At what price were the 25,000 OKYO (OKYO) shares acquired?

The 25,000 OKYO Pharma common shares were acquired at a reported price of $1.40 per share. The transaction is classified as a grant/award acquisition rather than an open-market purchase, and it increased Cerrone’s indirect holdings through Panetta Partners Limited.

Was the OKYO (OKYO) insider transaction a grant or an open-market buy?

The transaction is characterized as a grant/award acquisition of 25,000 common shares, not an open-market purchase. It is reported as a non-derivative acquisition of common stock, held indirectly through Panetta Partners Limited, with a price of $1.40 per share.

Was the latest OKYO (OKYO) insider transaction under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is unchecked, meaning the transaction was not affirmed as made under a Rule 10b5-1 trading plan. No footnotes indicate a separate trading arrangement, so the timing is not identified as pre-arranged in that manner.

Is Gabriele M. Cerrone a ten percent owner of OKYO (OKYO)?

Yes. In the insider report, Gabriele M. Cerrone is identified as both a director and a ten percent owner of OKYO Pharma Ltd. His indirect holdings after the reported transaction amount to 10,851,416 common shares, held via Panetta Partners Limited.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CERRONE GABRIELE M

(Last) (First) (Middle)

14-15 CONDUIT ST

(Street)

LONDON W1S 2XJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	07/20/2026		A		25,000	A	$1.4	10,851,416	I	Via Panetta Partners Limited

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Gabriele M. Cerrone	07/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)